Core Viewpoint - He Eye Hospital (301103) expects a net profit attributable to shareholders of 24 million to 36 million for 2025, representing a year-on-year growth of 187.60% to 231.40% [1] Group 1: Performance Improvement - The company has achieved a turnaround from loss to profit during the reporting period, driven by business structure optimization, effective cost control, and the disposal of inefficient assets [1] - Significant enhancement in profitability is attributed to the continuous optimization of the business structure, with a focus on high-margin refractive and optical businesses [1] Group 2: Cost and Efficiency Management - The company has implemented refined operational management, achieving cost reduction and efficiency improvement through centralized procurement optimization, supply chain efficiency enhancement, and digital operations [1] - These measures have contributed to the overall improvement in profitability [1] Group 3: Asset Optimization - The company has actively integrated, adjusted, or divested certain business units that have long-term poor performance or weak strategic synergy, further optimizing asset allocation efficiency [1]

Core Viewpoint - The company is expected to turn a profit in 2025, reversing previous losses due to optimized business structure, effective cost control, and the clearing of inefficient assets [1][2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a turnaround from loss to profit, indicating a positive shift in financial performance [1]. Group 2: Reasons for Performance Change - Continuous optimization of the business structure has driven growth, particularly in high-margin refractive and optical businesses [2]. - Significant results from cost and expense management have been achieved through refined operational management, centralized procurement, and enhanced supply chain efficiency [2]. - The company has actively integrated, adjusted, or divested underperforming business units to improve asset allocation efficiency [2]. Group 3: Additional Information - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an accounting firm [3]. - Final financial data will be disclosed in the company's 2025 annual report [3].

报告期内，公司业绩实现扭亏为盈，得益于业务结构优化、成本费用有效控制及低效资产出清，公司盈 利能力显著增强，具体原因如下：1.持续优化业务结构，高毛利业务驱动增长：公司推进业务结构优 化，加大对高毛利的屈光业务与视光业务的投入和发展所致。2.成本与费用管控成效显著：公司全面推 行精细化运营管理，通过集中采购优化、供应链效率提升、数字化运营等赋能，实现降本增效，从而带 动了整体盈利能力的提升。3.推进低效资产出清：公司对部分长期效益不佳或战略协同性较弱的业务单 元实施了主动整合、调整或剥离，进一步优化了资产配置效率。 格隆汇1月27日丨何氏眼科(301103.SZ)公布，预计2025年归属于上市公司股东的净利润2,400万元–3,600 万元，同比扭亏为盈，扣除非经常性损益后的净利润1,100万元–1,650万元，同比扭亏为盈。 ...

Core Viewpoint - The resignation of Zhou Jinfeng, the company's director and board secretary, is noted, and the company is taking steps to ensure continuity in its operations and governance [1] Group 1: Management Changes - Zhou Jinfeng submitted a written resignation report due to personal reasons, effective immediately upon delivery [1] - Zhou will no longer hold any position within the company after his resignation [1] - The company’s general manager, He Xingru, will temporarily assume the duties of the board secretary until a new appointment is made [1] Group 2: Financial Performance - For the period from January to September 2025, the company reported revenue of 855 million yuan, a year-on-year decrease of 1.11% [1] - The net profit attributable to shareholders for the same period was 54 million yuan, reflecting a significant year-on-year increase of 232.18% [1] - The increase in net profit is attributed to the company's focus on enhancing medical services, optimizing the supply chain, and reducing operational costs through various measures [1]

Core Viewpoint - Huaxia Eye Hospital (301267) is focusing on increasing the revenue share from refractive, optical, and presbyopia services to 70%-80% in the future, currently standing at approximately 40% for these services and 60% for cataract and other eye disease services [1] Group 1 - The current revenue distribution for Huaxia Eye Hospital's Beijing branch is approximately 40% from refractive and optical services and 60% from cataract and other eye disease services [1] - The company is intensifying efforts to develop refractive, optical, and presbyopia services [1] - The target for future revenue composition is to achieve a 70%-80% share from refractive, optical, and presbyopia services [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company reported a revenue of 2.139 billion yuan for H1 2025, representing a year-over-year increase of 4.31%, and a net profit attributable to shareholders of 282 million yuan, up 6.20% year-over-year [4][10] - The introduction of new surgical techniques has significantly boosted the company's refractive business, leading to a revenue of 789 million yuan in H1 2025, which is a 13.75% increase year-over-year [12] - The company has established a nationwide medical network with 64 specialized eye hospitals and 67 vision centers, enhancing its service coverage across various regions [13] Financial Performance Summary - For H1 2025, the company's gross margin was 45.20%, a slight decrease of 0.64 percentage points year-over-year, but improved in Q2 2025 to 45.44%, reflecting a recovery from previous impacts [11] - The company expects revenues for 2025-2027 to be 4.379 billion, 4.878 billion, and 5.479 billion yuan respectively, with year-over-year growth rates of 8.74%, 11.39%, and 12.32% [14] - The net profit attributable to shareholders is projected to be 570 million, 692 million, and 811 million yuan for the same period, with growth rates of 33.05%, 21.27%, and 17.21% respectively [14]

Summary of Medical Services Industry Conference Call Industry Overview - The medical services industry experienced a slight revenue increase of 0.2% to 36 billion in the first half of 2024, with a decline in the second quarter due to high base effects from the previous year [1][2] - Consumer medical services, particularly in ophthalmology, showed resilience, while serious medical service companies faced a revenue decline of 15%-20% due to high base effects and DRG/DIP consulting fees [1][4] Key Insights and Arguments - **Ophthalmology Sector Performance**: - Aier Eye Hospital's refractive and optical businesses achieved double-digit growth, leading the industry [1][5] - Other companies in the cataract business experienced declines due to the impact of crystal procurement, but a recovery is expected in the second half of the year [1][5] - The price war in refractive services is diminishing, and the demand for optical services is expected to rise due to the conclusion of the youth myopia prevention plan [1][5][8] - **Medicare Policy Impact**: - From January to July, the Medicare fund showed stable income growth of 7% and a spending decrease of 1%, indicating pressure on the expenditure side [9] - Data from cities like Chongqing, Tianjin, and Guangxi suggest steady outpatient visits, with expectations for recovery in demand and reporting in the second half of the year [9] - **Aier Eye Hospital's Strategic Expansion**: - The company aims to increase its overseas market share from the current 10-15% to 30-50% [1][10] - New business opportunities include advanced refractive procedures, multi-focus cataract upgrades, and presbyopia surgeries, with AI technology expected to enhance operational efficiency [1][10] Company-Specific Performance - **Aier Eye Hospital**: - Reported a 9% revenue growth and a 14% increase in net profit excluding non-recurring items in the first half of 2024 [3][8] - The average selling price (ASP) in refractive services increased by approximately 5% [5][8] - **International Medical**: - Faced operational pressure with a 16% revenue decline but managed to reduce net profit loss by 15% through improved diagnostic efficiency and optimized inpatient services [3][11] - The proton center is set to commence operations, and the aesthetic medical business is expected to grow significantly [11] Future Development Expectations - The second half of 2024 is anticipated to show optimistic trends for the medical services industry, with potential stock price opportunities due to accelerated company performance [3][12] - Policy changes, such as the introduction of provincial payment details and the expansion of prepayment and real-time settlement, are expected to positively impact the industry [12][13] - The overall beta slope of the industry is expected to improve, indicating a recovery in company performance and elasticity [13]

Core Viewpoint - The company reported its 2025 interim results, showing revenue growth and stable performance in key business segments despite some pressure on gross margins due to new hospital openings and policy changes [1][2]. Financial Performance - For H1 2025, the company achieved revenue of 11.507 billion yuan, an increase of 9.12%, and a net profit attributable to shareholders of 2.051 billion yuan, up by 0.05%. The net profit excluding non-recurring items was 2.040 billion yuan, reflecting a growth of 14.30% [1]. - In Q2 2025, the company recorded revenue of 5.481 billion yuan, a rise of 2.47%, while the net profit attributable to shareholders decreased by 12.97% to 1.001 billion yuan. The net profit excluding non-recurring items was 980 million yuan, up by 4.03% [1]. Operational Highlights - The company experienced growth in outpatient visits and surgeries, with outpatient visits reaching 9.2483 million, an increase of 16.47%, and surgeries totaling 879,000, up by 7.63% [2]. - The overall gross margin was 48.56%, a decline of 0.88 percentage points year-on-year, primarily due to the lower gross margins from recently acquired hospitals and increased depreciation from new large-scale hospitals [2]. Business Segment Performance - The refractive vision correction business grew by 11.14% to 4.618 billion yuan, while the optical business increased by 14.73% to 2.720 billion yuan, and the cataract business saw a revenue of 1.781 billion yuan, up by 2.64% [3]. - Growth in these segments was driven by technological upgrades, an expanded medical network, and proactive responses to changes in healthcare policies [3]. Strategic Initiatives - The company is advancing its digital transformation with the establishment of "AI Smart Ophthalmology Hospitals" and the development of an "AI Ophthalmologist" [4]. - Organizational management has been optimized through regional consolidations and integrated management models to enhance operational efficiency [4]. - The company distributed dividends of 1.487 billion yuan for the 2024 fiscal year, representing 41.82% of net profit attributable to shareholders, reflecting a commitment to shareholder returns [4]. Future Outlook - The company anticipates revenue growth for 2025-2027, projecting revenues of 23.065 billion yuan, 25.596 billion yuan, and 28.541 billion yuan, with year-on-year growth rates of 9.9%, 11.0%, and 11.5% respectively [5]. - Net profit attributable to shareholders is expected to reach 4.127 billion yuan, 4.770 billion yuan, and 5.484 billion yuan for the same period, with growth rates of 16.1%, 15.6%, and 15.0% respectively [5].

Investment Rating - The report maintains a "Buy" rating for the company [2][8] Core Insights - The company's performance in the first half of 2025 met expectations, with total revenue of 1.459 billion yuan, a year-on-year increase of 2.74%, and a net profit attributable to shareholders of 14.67 million yuan, a decline of 66.12% year-on-year [8] - The company is actively pursuing a "national chain + regional integration" strategy, having added two hospitals in the first half of 2025, bringing the total to 36 eye hospitals and 4 outpatient departments [8] - The company's mature hospitals have shown strong profitability, contributing a total profit of 132 million yuan in the first half of 2025 [8] - The revenue from cataract services has declined due to the impact of centralized procurement of artificial lenses, while refractive services remain a strong segment with a revenue increase of 4.13% [8] - The report projects a net profit of 82 million yuan for 2025, with significant growth expected in 2026 and 2027 [8] Financial Data and Profit Forecast - Total revenue projections for 2025 are set at 2.981 billion yuan, with a year-on-year growth rate of 11.3% [7] - The net profit attributable to shareholders is expected to turn positive at 82 million yuan in 2025, with further increases to 166 million yuan in 2026 and 282 million yuan in 2027 [7] - The report indicates a projected price-to-sales (PS) ratio of 2.7X for 2025, with a target price of 54.74 yuan per share, representing a potential upside of 28.0% from the latest closing price [8]

Core Insights - The company reported a revenue of 1.459 billion yuan for the first half of 2025, representing a year-on-year growth of 2.74%, while the net profit attributable to shareholders decreased by 66.12% to 14.6675 million yuan [1] - The decline in profit margins is attributed to a slowdown in overall demand and intensified industry competition, alongside the implementation of national policies affecting cataract surgery revenue [1] - The company continues to pursue a "national chain + regional integration" strategy, establishing a network of 36 specialized eye hospitals and 4 outpatient clinics across the country by June 30, 2025 [1] Business Segment Performance - The refractive business remains a key revenue driver, generating 720 million yuan, a 4.13% increase year-on-year [2] - Despite challenges from national procurement policies, the cataract business achieved 288 million yuan in revenue through the promotion of advanced surgical techniques [2] - The vision care segment, supported by marketing and service quality improvements, generated 190 million yuan, maintaining stable growth [2] - The comprehensive eye disease segment, addressing various conditions, reported a revenue of 243 million yuan, marking a 7.39% year-on-year increase and emerging as a new growth area for the company [2]